Is it time to Buy before this week’s earning report Kalvista Pharmaceuticals Stock Forecast, Price & News (NASDAQ:KALV)

0
770

Earnings results for Kalvista Pharmaceuticals Stock Forecast, Price & News (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. is estimated to report earnings on 09/14/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.6. The reported EPS for the same quarter last year was $-0.42.

Kalvista Pharmaceuticals last released its earnings results on July 1st, 2020. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.28. The company had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $2.05 million. Kalvista Pharmaceuticals has generated ($1.64) earnings per share over the last year. Kalvista Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, September 14th, 2020 based off prior year’s report dates.

Analyst Opinion on Kalvista Pharmaceuticals Stock Forecast, Price & News (NASDAQ:KALV)

3 Wall Street analysts have issued ratings and price targets for Kalvista Pharmaceuticals in the last 12 months. Their average twelve-month price target is $27.50, predicting that the stock has a possible upside of 102.06%. The high price target for KALV is $30.00 and the low price target for KALV is $25.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Kalvista Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $27.50, Kalvista Pharmaceuticals has a forecasted upside of 102.1% from its current price of $13.61. Kalvista Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Kalvista Pharmaceuticals Stock Forecast, Price & News (NASDAQ:KALV)

Kalvista Pharmaceuticals does not currently pay a dividend. Kalvista Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Kalvista Pharmaceuticals Stock Forecast, Price & News (NASDAQ:KALV)

In the past three months, Kalvista Pharmaceuticals insiders have not sold or bought any company stock. Only 18.00% of the stock of Kalvista Pharmaceuticals is held by insiders. 89.09% of the stock of Kalvista Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Kalvista Pharmaceuticals Stock Forecast, Price & News (NASDAQ:KALV

Earnings for Kalvista Pharmaceuticals are expected to decrease in the coming year, from ($2.58) to ($3.23) per share. The P/E ratio of Kalvista Pharmaceuticals is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Kalvista Pharmaceuticals is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Kalvista Pharmaceuticals has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here